Schedule 13G ownership disclosure
Avalo Therapeutics, Inc.
Common Stock, $0.001 par value · CUSIP: 05338F306
Event date: 2026-10-22
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Trails Edge Capital Partners, LP
Shares: 2,803,761.00 · Class: 5.2%
- Trails Edge Biotechnology Master Fund, LP
Shares: 2,803,761.00 · Class: 5.2%
- Ortav Yehudai
Shares: 2,803,761.00 · Class: 5.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001493152-26-049273
- Form type
- SCHEDULE 13G
- Filer
- Trails Edge Capital Partners, LP
- CIK
- CIK 2077247
- Filed
- Oct 29, 2026
- Reporting period
- Oct 22, 2026
- Description
- Schedule 13G beneficial ownership